Trial Profile

Evaluation of Antibody Persistence at 3.5 and 4.5 Years of Age in Healthy Children After Primary Series and Booster Vaccination With Investigational (DTaP-IPV-Hep B-PRP~T) or Infanrix Hexa Vaccines in Latin America [EXTENSION OF PROFILES 700058507 AND 700229466]

Status: Completed

Phase of Trial: Phase III

Latest Information Update: 01 May 2016

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Hib-DTaP-hepatitis B-poliovirus vaccine (Primary) ; Hib DTaP hepatitis B poliovirus vaccine (Infanrix hexa); Pneumococcal 7-valent CRM197 vaccine conjugate; RIX 4414
Indications Diphtheria; Haemophilus meningitis; Hepatitis B; Pertussis; Poliomyelitis; Tetanus
Focus Pharmacodynamics; Registrational
Sponsors Sanofi Pasteur

04 Jan 2016 Status changed from active, no longer recruiting to completed, according to ClinicalTrials.gov record.
22 Nov 2013 New trial record

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com